Sellas Life Sciences is trading 4.04% down at $11.40 on October 15, 2026, with no new company-specific catalyst reported. - Prior institutional-ownership headlines were positive and appeared before this session. - Investors remain focused on the pending REGAL final analysis, though there is no clear evidence it caused the decline. - The broader biotech sector is higher, so sector weakness does not explain the move.